argenx

What argenx does

argenx is a global commercial-stage immunology company founded in 2008 and headquartered in Amsterdam, Netherlands, with primary R&D operations in Ghent, Belgium and US operations in Boston. The company's core technology is its neonatal Fc receptor (FcRn) blockade platform, anchored by efgartigimod, a human IgG1 antibody fragment that binds FcRn with high affinity to reduce pathogenic IgG autoantibodies. Efgartigimod is commercialized as VYVGART (intravenous) and VYVGART Hytrulo (subcutaneous, co-formulated with Halozyme's ENHANZE technology), initially approved for generalized myasthenia gravis in anti-AChR antibody positive adults and, as of May 2026, expanded to all adult gMG serotypes. Additional regulatory approvals include CIDP (FDA) and UK MHRA approval, with breakthrough therapy designation for immune-mediated necrotizing myopathy.

argenx generates revenue primarily through direct global product net sales of the VYVGART franchise, priced at approximately $870,000 per patient per year. The company operates an enterprise field sales motion, distributing through specialty pharmacy networks and direct provider relationships across the US, Europe, UK, Japan, China (via Zai Lab), and additional markets. FY2025 product net sales reached $4.2B (+90% YoY), with the company achieving first-year operating profitability of $1.1B and net income of $1.3B. The pipeline is expanding to 10 clinical-stage molecules by end of 2026, including empasiprubart (Phase 3 for CIDP/MMN), adimanebart (Phase 2 for SMA/CMS/ALS), and indication-expansion programs for efgartigimod in myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis, supporting the company's Vision 2030 goal of 50,000 patients across 10 labeled indications.

Name

argenx

Legal name

argenx SE

Website

https://argenx.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

argenx is a global immunology company that commercializes VYVGART, the first approved FcRn blocker, treating patients with severe autoimmune diseases such as generalized myasthenia gravis and CIDP through direct sales to healthcare providers worldwide.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Immunology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Autoimmune disease therapeutics
• FcRn antibody blockers
• Biopharmaceutical products
• Immunology drug development
• Neurology specialty drugs

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations

Revenue model

1. VYVGART Product Sales: argenx generates revenue primarily through global product net sales of VYVGART (efgartigimod alfa and VYVGART Hytrulo). VYVGART is approved for generalized myasthenia gravis in adult patients who are anti-AChR antibody positive, with recent label expansion to all adult gMG patients regardless of serotype. The company also generates product net sales from both the intravenous infusion and subcutaneous injection formulations.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

argenx develops, manufactures, and commercializes FcRn blocker antibody therapeutics for severe autoimmune diseases. Its commercial products are VYVGART (efgartigimod alfa-fcab), an intravenous FcRn blocker, and VYVGART Hytrulo, a subcutaneous co-formulation with hyaluronidase-qvfc, both approved for generalized myasthenia gravis with Hytrulo additionally approved for CIDP. The company sells these products directly to healthcare providers, hospitals, and specialty pharmacy networks globally, and is advancing a pipeline of additional autoimmune candidates including empasiprubart and adimanebart.

Product overview

argenx is a global immunology company that commercializes the first approved neonatal Fc receptor (FcRn) blocker, VYVGART (efgartigimod alfa-fcab), and its subcutaneous formulation VYVGART Hytrulo. VYVGART is approved for generalized myasthenia gravis across all adult serotypes. The company is advancing a pipeline of autoimmune disease candidates including empasiprubart (Phase 3 for CIDP/MMN) and adimanebart (Phase 2 for SMA/CMS/ALS), with multiple indication expansion programs for VYVGART including myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis.

Differentiator

Problem solved

Functional benefit

Brands

• VYVGART: Brand name for argenx's approved FcRn blocker drug (efgartigimod) marketed for generalized myasthenia gravis and other autoimmune indications.

Products and services

• VYVGART (efgartigimod alfa-fcab) Intravenous neonatal Fc receptor (FcRn) blocker antibody fragment that reduces pathogenic IgG antibodies. Approved for adult patients with generalized myasthenia gravis across all serotypes including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.
• VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous formulation of efgartigimod co-formulated with Halozyme ENHANZE technology for easier administration via prefilled syringe. Approved for generalized myasthenia gravis across all adult serotypes and for chronic inflammatory demyelinating polyneuropathy (CIDP).
• Empasiprubart (ARGX-117) Investigational FcRn-targeting antibody candidate in Phase 3 development for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), part of argenx's strategy to expand its autoimmune franchise beyond efgartigimod.
• Adimanebart (ARGX-119) Investigational antibody in Phase 2 development for spinal muscular atrophy (SMA), Phase 1 for congenital myasthenic syndromes (CMS), and a Phase 2a study for amyotrophic lateral sclerosis (ALS), targeting the neuromuscular junction.

Quantifiable outcome

• 4.04-point improvement in MGII PRO ocular scores at Week 4 vs 1.99 for placebo (p=0.012)
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• PlaniswareminorOthers · 10 June 2026Customer testimonial at Planisware's Exchange26 EMEA conference in Paris. argenx presented alongside ABB, Safran, Europol, Novo Nordisk, IBSA, and Expanscience on AI-driven innovations for project and portfolio management.
• MindWalk HoldingsminorStrategic or Co-development Partner · 18 May 2026MindWalk's antibody discovery work produced discovery-originated drug candidates for argenx among its over 20 programs in active Phase 1-3 clinical trials. MindWalk's platform includes proprietary wet-lab antibody discovery and the HYFT biological intelligence infrastructure.
• Zai LabcoreStrategic or Co-development Partner · 1 January 2025Collaboration for development and commercialization of VYVGART in Greater China. Zai Lab reported $94.2 million in full-year VYVGART franchise revenue and continues to advance pipeline programs including povetacicept in IgA nephropathy.
• Halozyme TherapeuticscoreTechnology or Integration · 1 January 2024Partnership for ENHANZE drug delivery technology enabling subcutaneous administration of VYVGART. Halozyme's ENHANZE technology enables subcutaneous injection of large volume biologics, supporting the VYVGART Hytrulo prefilled syringe formulation. VYVGART Hytrulo has exceeded expectations at $4.2 billion in total revenues according to Halozyme projections.
• IQVIAminorImplementation/ SI/ Consulting Partner · 1 January 2024Strategic partnership for technology-enabled pharmacovigilance services, supporting argenx's global safety monitoring and regulatory compliance activities.
• genOwaycoreStrategic or Co-development Partner · 1 January 2024International consortium led by genOway and including argenx, Innate Pharma, and Vir Biotechnology developed the genO-hFcγR mouse model enabling more accurate prediction of therapeutic antibody efficacy and safety in humans. The model addresses species-specific discrepancies in Fcγ receptors that cause unreliable results in standard laboratory mice, helping rank antibody candidates and reduce expensive late-stage clinical failures.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Sanofi is a global immunology leader anchored by Dupixent and is expanding its autoimmune and rare disease portfolio, competing with argenx for autoimmune market share and specialty pharmacy channels.
• AstraZeneca: AstraZeneca, through its Alexion acquisition, holds a leading position in rare autoimmune and complement-mediated diseases (e.g., ravulizumab), positioning it as a broad incumbent competing for rare autoimmune patients and specialty channel access.
• AbbVie: AbbVie is a broad incumbent in autoimmune diseases with Humira, Skyrizi, and Rinvoq dominating immunology markets; argenx competes for the same prescriber base and patient pool across overlapping autoimmune conditions.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals was named Bank of America's other top biotech pick for 2026 alongside argenx and is a comparable mid-to-large cap commercial-stage biotech with concentrated franchise economics.
• Bristol-Myers Squibb: Bristol-Myers Squibb maintains a substantial immunology franchise (Sotyktu, Zeposia) and competes for autoimmune market share and specialty care prescribers that drive VYVGART adoption.

Regional players

• Zai Lab: Zai Lab is argenx's strategic partner commercializing VYVGART in Greater China, reporting $94.2M in franchise revenue; comparable as a regional commercializer of innovative autoimmune therapies in China.

Direct peers

• Immunovant: Immunovant is a clinical-stage biotech developing batoclimab (IMVT-1401), an FcRn blocker targeting autoimmune diseases including gMG and other indications, making it a direct mechanism competitor to argenx.
• Johnson & Johnson: Johnson & Johnson is developing nipocalimab (acquired via Momenta), an FcRn blocker in late-stage trials across multiple autoimmune indications, directly competing with argenx's pipeline expansion strategy beyond gMG.
• UCB: UCB commercializes rozanolixizumab, an FcRn antagonist approved in the EU for generalized myasthenia gravis, making it the closest direct competitor to argenx's VYVGART in the same mechanism and indication.

Others

• Halozyme Therapeutics: Halozyme is the technology partner supplying ENHANZE drug delivery technology that enables argenx's VYVGART Hytrulo subcutaneous formulation; it is an enabling supplier whose commercial success is partially tied to argenx's franchise performance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@argenxglobal
• Facebookfacebook.com/argenxglobal
• LinkedInlinkedin.com/company/argenx
• Xx.com/argenxglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about argenx